Nefopam enhances the protective activity of antiepileptics against maximal electroshockinduced convulsions in mice

Beaver, 1977, A comparison of the analgesic effect of intramuscular nefopam and morphine in patients with post-operative pain, J Clin Pharmacol, 17, 579, 10.1177/009127007701701005 Biella, 2003, Neuronal sensitization and its behavioral correlates in a rat model of neuropathy are prevented by a cyclic analog of orphenadrine, J Neurotrauma, 20, 593, 10.1089/089771503767168519 Boissier, 1960, A simple novel method to explore tranquilizer activity: the chimney test, Med Exp (Basel, 3, 81, 10.1159/000134913 Borowicz, 2000, Influence of D(–)CPP and (±)CPP upon the protective action of conventional antiepileptic drugs against electroconvulsions in mice, Pol J Pharmacol, 52, 431 Czuczwar, 1984, Effects of excitatory amino-acid antagonists on the anticonvulsive action of phenobarbital or diphenylhydantoin in mice, Eur J Pharmacol, 100, 357, 10.1016/0014-2999(84)90013-X Czuczwar, 2009, Influence of orphenadrine upon the protective activity of various antiepileptics in the maximal electroshock-induced convulsions in mice, Pharmacol Rep, 61, 732, 10.1016/S1734-1140(09)70127-6 Deckers, 2000, Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed, Epilepsia, 41, 1364, 10.1111/j.1528-1157.2000.tb00111.x Diáz-Trelles, 1999, Terfenadine prevents NMDA receptor-dependent and independent toxicity following sodium channel activation, Brain Res, 842, 478, 10.1016/S0006-8993(99)01828-4 Diáz-Trelles, 2000, Antihistamine terfenadine potentiates NMDA receptor-mediated calcium influx, oxygen radical formation, and neuronal death, Brain Res, 880, 17, 10.1016/S0006-8993(00)02627-5 Esposito, 1986, Evidence of the involvement of dopamine in the analgesic effect of nefopam, Eur J Pharmacol, 128, 157, 10.1016/0014-2999(86)90762-4 Fernandez-Sanchez, 2002, Nefopam, an analogue of orphenadrine, protects against both NMDA receptor-dependent and independent vera- tridine induced neurotoxicity, Amino Acids, 23, 31, 10.1007/s00726-001-0106-6 Fernández-Sánchez, 2001, Novel effect of nefopam preventing cGMP increase, oxygen radical formation and neuronal death induced by veratridine, Neuropharmacology, 41, 935, 10.1016/S0028-3908(01)00139-3 Fuller, 1993, Evaluation of nefopam as a monoamine uptake inhibitor in vivo in mice, Neuropharmacology, 32, 995, 10.1016/0028-3908(93)90064-A Girard, 2004, Role of the histamine system in nefopam-induced antinociception in mice, Eur J Pharmacol, 503, 63, 10.1016/j.ejphar.2004.09.030 Hunskaar, 1987, Involvement of central serotonergic pathways in nefopam-induced antinociception, Eur J Pharmacol, 138, 77, 10.1016/0014-2999(87)90339-6 Ishikawa, 2007, Influences of histamine H1 receptor antagonists on maximal electroshock seizure in infant rats, Biol Pharm Bull, 30, 477, 10.1248/bpb.30.477 Kamei, 1998, Hista- minergic mechanisms in amygdaloid-kindled seizures in rats, Epilepsy Res, 30, 187, 10.1016/S0920-1211(98)00005-9 Kerr, 2010, Fatal nefopam overdose, Emerg Med J, 27, 407, 10.1136/emj.2009.082974 Kim, 1997, NMDA receptors are important for both mechanical and thermal allodynia from peripheral nerve injury in rats, Neuroreport, 8, 2149, 10.1097/00001756-199707070-00011 Klohs, 1972, Ben- zoxacines: a new chemical class of centrally acting skeletal muscle relaxants, Arzneimittelforschung, 22, 132 Kornhuber, 1995, Orphenadrine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist: binding and patch clamp studies, J Neural Transm Gen Sect, 102, 237, 10.1007/BF01281158 Litchfield, 1949, A simplified method of evaluating dose-effect experiments, J Pharmacol Exp Ther, 96, 99 Łuszczki, 2006, Iso- bolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maxi-mal electroshock-induced seizure model, Naunyn-Schmiedeberg’s Arch Pharmacol, 373, 169, 10.1007/s00210-006-0055-4 Makarska-Białek, 2005, Influence of the antagonist of the glycine site of NMDA receptors, MRZ 2/576, on the anticonvulsant activity of conventional antiepileptic drugs in mice, Pharmacol Rep, 57, 458 Novelli, 2007, Nefopam is more potent than carbamazepine for neuroprotection against veratridine in vitro and has anticonvulsant properties against both elec-trical and chemical stimulation, Amino Acids, 32, 323, 10.1007/s00726-006-0419-6 Piercey, 1981, Spinal and supraspinal sites for morphine and nefopam analgesia in the mouse, Eur J Pharmacol, 74, 135, 10.1016/0014-2999(81)90523-9 Pillans, 1995, Adverse reactions associated with nefopam, N Z Med J, 108, 382 Safar, 2010, Magnesium supplementation enhances the anticonvulsant potential of valproate in pentylenetetrazol-treated rats, Brain Res, 1334, 58, 10.1016/j.brainres.2010.03.076 Socala, 2010, Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models, Pharmacol Rep, 62, 392, 10.1016/S1734-1140(10)70279-6 Świąder, 2001, Influence of chronic treatment with H1 receptor antagonists on the anticonvulsant activity of antiepileptic drugs, Pol J Pharmacol, 53, 93 Taniguchi, 2010, The effects of nefopam on the gain and maximum intensity of shivering in healthy volunteers, Anesth Analg, 7, 409, 10.1213/ANE.0b013e3181e332bb Verleye, 2004, Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents, Brain Res, 1013, 249, 10.1016/j.brainres.2004.04.035